A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis
Latest Information Update: 05 Feb 2025
Price :
$35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Roche
- 22 Jan 2025 New trial record